methyl (1'R,2S,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate
| Title | Journal |
|---|---|
| Aldosterone activates transcription factor Nrf2 in kidney cells both in vitro and in vivo. | Antioxidants & redox signaling 20141120 |
| Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. | Journal of medicinal chemistry 20140522 |
| Prostate effect in dogs with the aldosterone receptor blocker eplerenone. | Toxicologic pathology 20130201 |
| WNK-OSR1/SPAK-NCC signal cascade has circadian rhythm dependent on aldosterone. | Biochemical and biophysical research communications 20121102 |
| Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration. | Journal of neurology 20121101 |
| Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. | Anesthesiology 20121101 |
| [Is eplerenone nephrotoxic?]. | Deutsche medizinische Wochenschrift (1946) 20121101 |
| Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone. | The American journal of cardiology 20121015 |
| Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. | Clinical cardiology 20121001 |
| Who needs a transplant and when? | Current opinion in organ transplantation 20121001 |
| Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. | Hypertension (Dallas, Tex. : 1979) 20121001 |
| Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy. | Journal of medicinal chemistry 20120927 |
| Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20120901 |
| A diastereoselective synthesis of 7α-nitromethyl steroid derivative and its use for an efficient synthesis of eplerenone. | Steroids 20120901 |
| Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20120901 |
| The role of aldosterone receptor antagonists in the management of heart failure: an update. | Cleveland Clinic journal of medicine 20120901 |
| Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. | Circulation 20120821 |
| Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. | Journal of human hypertension 20120801 |
| Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury. | International journal of obesity (2005) 20120801 |
| Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. | The Journal of veterinary medical science 20120801 |
| Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). | European journal of heart failure 20120801 |
| Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome. | Therapeutic advances in cardiovascular disease 20120801 |
| Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. | ChemMedChem 20120801 |
| Eplerenone is not superior to older and less expensive aldosterone antagonists. | The American journal of medicine 20120801 |
| Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. | The Journal of clinical investigation 20120702 |
| Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. | Free radical biology & medicine 20120701 |
| The 2012 ESC Guidelines on Heart Failure. | European heart journal 20120701 |
| Eplerenone for the treatment of cardiovascular disorders. | Expert review of cardiovascular therapy 20120701 |
| The meaning of hypokalemia in heart failure. | International journal of cardiology 20120628 |
| Cisplatin-induced acute renal failure in mice is mediated by chymase-activated angiotensin-aldosterone system and interleukin-18. | European journal of pharmacology 20120615 |
| Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. | Journal of the American Society of Nephrology : JASN 20120601 |
| Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. | Hypertension (Dallas, Tex. : 1979) 20120601 |
| Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. | Hypertension (Dallas, Tex. : 1979) 20120601 |
| Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. | European journal of heart failure 20120601 |
| Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS. | Journal of cardiac failure 20120601 |
| Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. | The Annals of pharmacotherapy 20120601 |
| Recent developments in the management of heart failure. | The Practitioner 20120601 |
| Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. | Molecular and cellular endocrinology 20120515 |
| Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. | Archives of medical science : AMS 20120509 |
| Heart failure: EMPHASIS-HF links eplerenone with reduced risk of new-onset AF. | Nature reviews. Cardiology 20120508 |
| Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. | Cancer research 20120501 |
| Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. | Hypertension (Dallas, Tex. : 1979) 20120501 |
| Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. | Journal of the American College of Cardiology 20120501 |
| Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120501 |
| Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone. | Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 20120501 |
| Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma. | The Journal of steroid biochemistry and molecular biology 20120401 |
| Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats. | Hypertension research : official journal of the Japanese Society of Hypertension 20120401 |
| Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. | Journal of cardiac failure 20120401 |
| Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats. | Diabetes & metabolism journal 20120401 |
| Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. | Molecular and cellular endocrinology 20120324 |
| Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. | Biochemical and biophysical research communications 20120309 |
| The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301 |
| Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120301 |
| Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice. | American journal of hypertension 20120301 |
| Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels. | Endocrinology 20120301 |
| Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. | Hypertension (Dallas, Tex. : 1979) 20120301 |
| Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats. | Diabetes, obesity & metabolism 20120201 |
| Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1. | Clinical and experimental nephrology 20120201 |
| Eplerenone use in primary aldosteronism during pregnancy. | Hypertension (Dallas, Tex. : 1979) 20120201 |
| Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. | The Journal of clinical endocrinology and metabolism 20120201 |
| Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. | Arteriosclerosis, thrombosis, and vascular biology 20120201 |
| Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. | Clinical pharmacology and therapeutics 20120201 |
| Eplerenone works. Does it matter how? | Expert review of cardiovascular therapy 20120201 |
| Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. | Circulation 20120117 |
| Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism. | Bioorganic & medicinal chemistry letters 20120115 |
| The effect of treatment on monocyte and lymphocyte cytokine release in patients with aldosteronoma. | Hypertension research : official journal of the Japanese Society of Hypertension 20120101 |
| The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. | European heart journal 20120101 |
| Eplerenone improved hypokalemia in a patient with Gitelman's syndrome. | Internal medicine (Tokyo, Japan) 20120101 |
| Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. | Current pharmaceutical design 20120101 |
| Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. | Drug design, development and therapy 20120101 |
| The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling. | PloS one 20120101 |
| How full is our antihypertensives pipeline? | Journal of pharmacology & pharmacotherapeutics 20120101 |
| Targeting NADPH oxidases in vascular pharmacology. | Vascular pharmacology 20120101 |
| Developments in heart failure 2011. | Congestive heart failure (Greenwich, Conn.) 20120101 |
| Mineralocorticoid receptor antagonist for renal protection. | Renal failure 20120101 |
| Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis. | Nephron extra 20120101 |
| Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study. | PloS one 20120101 |
| Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats. | Annals of hepatology 20120101 |
| The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db/db mice. | Cardiovascular diabetology 20120101 |
| Cardiovascular magnetic resonance in systemic hypertension. | Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20120101 |
| The Relationship between Reactive Oxygen Species and Cardiac Fibrosis in the Dahl Salt-Sensitive Rat under ACEI Administration. | Veterinary medicine international 20120101 |
| Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. | Cardiology journal 20120101 |
| Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. | PloS one 20120101 |
| Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities. | International journal of hypertension 20120101 |
| Antioxidants in kidney diseases: the impact of bardoxolone methyl. | International journal of nephrology 20120101 |
| Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats. | PloS one 20120101 |
| Sex and gender differences in cardiovascular drug therapy. | Handbook of experimental pharmacology 20120101 |
| Degradation Pathway for Eplerenone by Validated Stability Indicating UP-LC Method. | ISRN pharmaceutics 20120101 |
| Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. | Journal of medicinal chemistry 20111222 |
| Mineralocorticoid receptor activation is crucial in the signalling pathway leading to the Anrep effect. | The Journal of physiology 20111215 |
| Study of the mechanisms of aldosterone prothrombotic effect in rats. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20111201 |
| Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells. | British journal of pharmacology 20111201 |
| Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. | Hypertension research : official journal of the Japanese Society of Hypertension 20111201 |
| Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. | European journal of heart failure 20111201 |
| Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension. | Clinical and experimental hypertension (New York, N.Y. : 1993) 20111201 |
| Improvement of sodium status to optimize the efficacy of Renin-Angiotensin system blockade. | Current hypertension reports 20111201 |
| What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated? | Current cardiology reports 20111201 |
| A sensitive and specific HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of isoforskolin in beagle dogs. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111201 |
| Heart failure and non-ST-segment elevation myocardial infarction: a review for a widespread situation. | European journal of internal medicine 20111201 |
| Mineralocorticoid receptor antagonists for heart failure. | Expert opinion on pharmacotherapy 20111201 |
| Mineralocorticoid receptor antagonists for heart failure. | Expert opinion on pharmacotherapy 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Mechanisms mediating sodium-induced pressor responses in the PVN of Dahl rats. | American journal of physiology. Regulatory, integrative and comparative physiology 20111101 |
| The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain. | Hypertension research : official journal of the Japanese Society of Hypertension 20111101 |
| Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. | European heart journal 20111101 |
| Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. | Circulation 20111101 |
| Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study. | Clinical nephrology 20111101 |
| Aldosterone stimulates the cardiac Na(+)/H(+) exchanger via transactivation of the epidermal growth factor receptor. | Hypertension (Dallas, Tex. : 1979) 20111101 |
| Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. | Journal of the American College of Cardiology 20111101 |
| The month after a novel tale on eplerenone, but with a different ending. | Journal of the American College of Cardiology 20111101 |
| Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. | American journal of physiology. Renal physiology 20111001 |
| The effect of body mass index and fasting glucose on the relationship between blood pressure and incident diabetes mellitus: a 5-year follow-up study. | Hypertension research : official journal of the Japanese Society of Hypertension 20111001 |
| Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%. | Internal and emergency medicine 20111001 |
| Clinical trials update from the European Society of Cardiology Heart Failure meeting 2011: TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSI-HF and EMPHASIS-HF. | European journal of heart failure 20111001 |
| Mineralocorticoid hypertension. | Indian journal of endocrinology and metabolism 20111001 |
| Pediatric endocrine hypertension. | Indian journal of endocrinology and metabolism 20111001 |
| Mild hyperkalemia and low eGFR a tedious recipe for cardiac disaster in the elderly: an unusual reversible cause of syncope and heart block. | Heart international 20110929 |
| Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20110901 |
| Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20110901 |
| Dehydroepiandrosterone-induced phosphorylation and translocation of FoxO1 depend on the mineralocorticoid receptor. | Hypertension (Dallas, Tex. : 1979) 20110901 |
| Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. | Hypertension (Dallas, Tex. : 1979) 20110901 |
| Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol. | Canadian journal of physiology and pharmacology 20110901 |
| Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. | Journal of clinical hypertension (Greenwich, Conn.) 20110901 |
| [Pharmacological sheet: eplerenone (Inspra), orally]. | Journal de pharmacie de Belgique 20110901 |
| The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis. | International journal of clinical and experimental pathology 20110815 |
| Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction. | Evidence-based medicine 20110801 |
| An ouabain-like factor is secreted from immortalized hypothalamic cells in an aldosterone-dependent manner. | Neurochemistry international 20110801 |
| Spironolactone is more effective than eplerenone at lowering blood pressure in patients with primary aldosteronism. | Journal of clinical hypertension (Greenwich, Conn.) 20110801 |
| Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). | Journal of cardiac failure 20110801 |
| Glucocorticoid and mineralocorticoid receptors regulate paracellular permeability in a primary cultured gill epithelium. | The Journal of experimental biology 20110715 |
| Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats. | Hypertension research : official journal of the Japanese Society of Hypertension 20110701 |
| Eplerenone, amlodipine and experimental hypertension: one plus one equals three. | Hypertension research : official journal of the Japanese Society of Hypertension 20110701 |
| [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications]. | Nephrologie & therapeutique 20110601 |
| Aldosterone antagonists in heart failure. | Journal of cardiovascular pharmacology and therapeutics 20110601 |
| Proinflammatory protein CARD9 is essential for infiltration of monocytic fibroblast precursors and cardiac fibrosis caused by Angiotensin II infusion. | American journal of hypertension 20110601 |
| Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism. | Hypertension research : official journal of the Japanese Society of Hypertension 20110601 |
| Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. | American journal of physiology. Renal physiology 20110601 |
| Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics. | Hepatology international 20110601 |
| Protective effects of eplerenone on podocyte injury in adriamycin nephropathy rats. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20110601 |
| Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. | European heart journal 20110501 |
| Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. | Hypertension research : official journal of the Japanese Society of Hypertension 20110501 |
| Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. | European journal of heart failure 20110501 |
| Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. | Kidney international 20110501 |
| A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. | Journal of hypertension 20110501 |
| Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ. | The American journal of pathology 20110501 |
| [The EMPHASIS-HF study]. | Giornale italiano di cardiologia (2006) 20110501 |
| Advances in cardiology: clinical trial update. | Future cardiology 20110501 |
| Investigating the function of an aldosterone response pathway in primary human adrenocortical cells obtained from Conn's and phaeochromocytoma patients. | European journal of pharmacology 20110425 |
| Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. | The American journal of cardiology 20110415 |
| Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives. | Journal of medicinal chemistry 20110414 |
| Eplerenone in mild heart failure. | The New England journal of medicine 20110407 |
| Eplerenone in mild heart failure. | The New England journal of medicine 20110407 |
| Eplerenone in mild heart failure. | The New England journal of medicine 20110407 |
| Eplerenone in mild heart failure. | The New England journal of medicine 20110407 |
| Timing of defibrillator implant after acute myocardial infarction: what's new? | Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20110401 |
| The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. | Current hypertension reports 20110401 |
| Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. | European heart journal 20110401 |
| Macrophage activation is responsible for loss of anticontractile function in inflamed perivascular fat. | Arteriosclerosis, thrombosis, and vascular biology 20110401 |
| Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. | European journal of heart failure 20110401 |
| [Heart failure]. | Deutsche medizinische Wochenschrift (1946) 20110401 |
| Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110301 |
| Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension. | Hypertension research : official journal of the Japanese Society of Hypertension 20110301 |
| Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. | Current heart failure reports 20110301 |
| Primary aldosteronism: A Japanese perspective. | Reviews in endocrine & metabolic disorders 20110301 |
| Treatment of primary aldosteronism: Where are we now? | Reviews in endocrine & metabolic disorders 20110301 |
| Eplerenone for gitelman syndrome in pregnancy. | Nephrology (Carlton, Vic.) 20110301 |
| Primary aldosteronism, diagnosis and treatment in Japan. | Reviews in endocrine & metabolic disorders 20110301 |
| Effects of spironolactone in spontaneously hypertensive adult rats subjected to high salt intake. | Clinics (Sao Paulo, Brazil) 20110301 |
| Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. | American journal of physiology. Renal physiology 20110201 |
| Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney. | Endocrinology 20110201 |
| Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. | Journal of hypertension 20110201 |
| Clinical Trials Update AHA Congress 2010. | Cardiovascular drugs and therapy 20110201 |
| Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-γ). | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20110201 |
| Eplerenone in patients with systolic heart failure and mild symptoms. | The New England journal of medicine 20110106 |
| Aldosterone antagonists--last man standing? | The New England journal of medicine 20110106 |
| Stereoselective construction of a steroid 5α,7α-oxymethylene derivative and its use in the synthesis of eplerenone. | Steroids 20110101 |
| High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. | Hypertension research : official journal of the Japanese Society of Hypertension 20110101 |
| 11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. | Endocrinology 20110101 |
| Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. | Journal of pharmacological sciences 20110101 |
| Treatment considerations with aldosterone receptor antagonists. | Journal of clinical hypertension (Greenwich, Conn.) 20110101 |
| Heart failure: Placing an EMPHASIS on the mineralocorticoid receptor--benefit of eplerenone in mild HF. | Nature reviews. Cardiology 20110101 |
| Evolution of ligand specificity in vertebrate corticosteroid receptors. | BMC evolutionary biology 20110101 |
| Resistant hypertension workup and approach to treatment. | International journal of hypertension 20110101 |
| Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy. | Journal of biomedicine & biotechnology 20110101 |
| Pathophysiology of resistant hypertension: the role of sympathetic nervous system. | International journal of hypertension 20110101 |
| Aldosteronism and resistant hypertension. | International journal of hypertension 20110101 |
| SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. | Journal of pharmacological sciences 20110101 |
| Cardiorenal syndrome in acute heart failure syndromes. | International journal of nephrology 20110101 |
| Adrenocortical causes of hypertension. | International journal of hypertension 20110101 |
| Role of the kidneys in resistant hypertension. | International journal of hypertension 20110101 |
| Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study. | Arzneimittel-Forschung 20110101 |
| Hyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy. | International journal of nephrology 20110101 |
| The causes, consequences, and treatment of left or right heart failure. | Vascular health and risk management 20110101 |
| Long-term use of aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis. | International journal of hypertension 20110101 |
| Cardiorenal syndrome: an unsolved clinical problem. | International journal of nephrology 20110101 |
| Pharmacological management of cardiorenal syndromes. | International journal of nephrology 20110101 |
| [Summary of the article: Zannad F, McMurray JJV, Krum H et al.; for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21]. | Kardiologia polska 20110101 |
| Diabetic microvascular complications: possible targets for improved macrovascular outcomes. | International journal of nephrology and renovascular disease 20110101 |
| Abiraterone acetate, an inhibitor of adrenal androgen synthesis in 'hormone refractory prostate cancer'. | Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20110101 |
| Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. | Vascular health and risk management 20110101 |
| Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. | International journal of hypertension 20110101 |
| Management of hypertension in high-risk ethnic minority with heart failure. | International journal of hypertension 20110101 |
| Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. | International journal of hypertension 20110101 |
| Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. | Indian journal of nephrology 20110101 |
| Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. | International journal of hypertension 20110101 |
| Animal models of calcific aortic valve disease. | International journal of inflammation 20110101 |
| Changes in the perceived epidemiology of primary hyperaldosteronism. | International journal of hypertension 20110101 |
| Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction. | Trials 20110101 |
| Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review. | Integrated blood pressure control 20110101 |
| Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients. | Integrated blood pressure control 20110101 |
| Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone. | Journal of translational medicine 20110101 |
| Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report. | Cardiovascular diabetology 20110101 |
| The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. | Journal of translational medicine 20110101 |
| Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. | PloS one 20110101 |
| Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population. | Neuropsychiatric disease and treatment 20110101 |
| Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure. | BMC cardiovascular disorders 20110101 |
| Simultaneous identification and quantification of canrenone and 11-α-hydroxy-canrenone by LC-MS and HPLC-UVD. | Journal of biomedicine & biotechnology 20110101 |
| Early peroxisome proliferator-activated receptor gamma regulated genes involved in expansion of pancreatic beta cell mass. | BMC medical genomics 20110101 |
| Novel Pharmacological Interventions to Maintain Sinus Rhythm after DC Cardioversion. | ISRN cardiology 20110101 |
| [Aldosterone blocker in heart failure: life prolonging even in mild symptoms]. | MMW Fortschritte der Medizin 20101202 |
| Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay. | Therapeutic drug monitoring 20101201 |
| Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. | Kidney international 20101201 |
| Review article: eplerenone: an underused medication? | Journal of cardiovascular pharmacology and therapeutics 20101201 |
| Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. | Endocrinology 20101201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20101201 |
| Increased renal alpha-epithelial sodium channel (ENAC) protein and increased ENAC activity in normal pregnancy. | American journal of physiology. Regulatory, integrative and comparative physiology 20101101 |
| BK channels and a new form of hypertension. | Kidney international 20101101 |
| Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. | American heart journal 20101101 |
| [Prothrombotic aldosterone action--a new side of the hormone]. | Postepy higieny i medycyny doswiadczalnej (Online) 20101018 |
| Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin. | The Journal of investigative dermatology 20101001 |
| Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. | Naunyn-Schmiedeberg's archives of pharmacology 20101001 |
| Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? | Clinical cardiology 20101001 |
| Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis. | European journal of pharmacology 20100910 |
| Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb. | American journal of hypertension 20100901 |
| Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100901 |
| Reduction of endothelial tight junction proteins is related to cerebral aneurysm formation in rats. | Journal of hypertension 20100901 |
| Aldosterone blockade in chronic kidney disease: can it improve outcome? | Current opinion in nephrology and hypertension 20100901 |
| Aldosterone and angiogenesis. | American journal of hypertension 20100901 |
| World Congress on the Insulin Resistance Syndrome, 2009: the kidney, the liver, and insulin resistance. | Diabetes care 20100901 |
| Genetic analyses of the chimeric CYP11B1/CYP11B2 gene in a Korean family with glucocorticoid-remediable aldosteronism. | Journal of Korean medical science 20100901 |
| Clinical Inquiries: Which drugs should post-MI patients routinely receive? | The Journal of family practice 20100901 |
| The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. | Clinical cardiology 20100901 |
| Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. | Journal of medicinal chemistry 20100826 |
| Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. | Journal of medicinal chemistry 20100826 |
| The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. | The Journal of pediatrics 20100801 |
| Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. | American journal of physiology. Heart and circulatory physiology 20100801 |
| Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. | Diabetes 20100801 |
| Drug mechanisms to help in managing resistant hypertension in obesity. | Current hypertension reports 20100801 |
| Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. | Clinical and experimental nephrology 20100801 |
| Mineralocorticoid receptor antagonists and the metabolic syndrome. | Current hypertension reports 20100801 |
| Novel therapeutic targets for hypertension. | Nature reviews. Cardiology 20100801 |
| Aldosterone inhibition and cardiovascular protection: more important than it once appeared. | Cardiovascular drugs and therapy 20100801 |
| Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy? | Drugs 20100709 |
| Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. | European heart journal 20100701 |
| Microvascular obstruction remains a portent of adverse remodeling in optimally treated patients with left ventricular systolic dysfunction after acute myocardial infarction. | Circulation. Cardiovascular imaging 20100701 |
| Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney. | Kidney & blood pressure research 20100701 |
| Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload. | Journal of hypertension 20100701 |
| Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro. | Revista espanola de cardiologia 20100701 |
| The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. | European journal of pharmacology 20100610 |
| Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. | Journal of human hypertension 20100601 |
| Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice. | American journal of physiology. Heart and circulatory physiology 20100601 |
| Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. | Hypertension research : official journal of the Japanese Society of Hypertension 20100601 |
| Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). | European journal of heart failure 20100601 |
| Activation of mineralocorticoid receptors by exogenous glucocorticoids and the development of cardiovascular inflammatory responses in adrenalectomized rats. | Endocrinology 20100601 |
| The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat. | International journal of molecular medicine 20100601 |
| Eplerenone in chronic renal disease: the EVALUATE trial. | Hypertension research : official journal of the Japanese Society of Hypertension 20100601 |
| Aortic cell apoptosis in rat primary aldosteronism model. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20100601 |
| Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. | Journal of medicinal chemistry 20100527 |
| Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction. | Journal of thrombosis and thrombolysis 20100501 |
| Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. | Journal of psychopharmacology (Oxford, England) 20100501 |
| Aldosterone stimulates the proliferation of uterine leiomyoma cells. | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20100501 |
| Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats. | Clinical and experimental pharmacology & physiology 20100501 |
| Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension. | Hypertension research : official journal of the Japanese Society of Hypertension 20100501 |
| Monocyte chemoattractant protein-1: a dichotomous role in cardiac remodeling following acute myocardial infarction in man? | Cytokine 20100501 |
| Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. | Circulation. Heart failure 20100501 |
| Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. | Hepatology research : the official journal of the Japan Society of Hepatology 20100501 |
| Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. | Future oncology (London, England) 20100501 |
| A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. | Health technology assessment (Winchester, England) 20100501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100501 |
| Physiologic tailoring of treatment in resistant hypertension. | Current cardiology reviews 20100501 |
| Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess. | American journal of physiology. Heart and circulatory physiology 20100401 |
| Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. | British journal of pharmacology 20100401 |
| Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure. | Journal of veterinary pharmacology and therapeutics 20100401 |
| Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. | Nephrology (Carlton, Vic.) 20100401 |
| Effect of angiotensin II on the WNK-OSR1/SPAK-NCC phosphorylation cascade in cultured mpkDCT cells and in vivo mouse kidney. | Biochemical and biophysical research communications 20100319 |
| Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. | The Journal of pharmacology and experimental therapeutics 20100301 |
| Involvement of mineralocorticoid receptor in high glucose-induced big mitogen-activated protein kinase 1 activation and mesangial cell proliferation. | Journal of hypertension 20100301 |
| Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall. | Experimental biology and medicine (Maywood, N.J.) 20100301 |
| Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. | Regulatory peptides 20100225 |
| Aldosterone receptor antagonists: effective but often forgotten. | Circulation 20100223 |
| [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system]. | MMW Fortschritte der Medizin 20100211 |
| Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective. | Journal of human hypertension 20100201 |
| Agents with antialdosterone properties should be the preferred diuretics for reducing hypertension related atrial fibrillation. | European journal of internal medicine 20100201 |
| Eplerenone improves vascular function and reduces platelet activation in diabetic rats. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20100201 |
| Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. | Journal of the American College of Cardiology 20100119 |
| Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice. | Atherosclerosis 20100101 |
| High-salt diet increases plasma adiponectin levels independent of blood pressure in hypertensive rats: the role of the renin-angiotensin-aldosterone system. | Journal of hypertension 20100101 |
| Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101 |
| Skeletal muscle insulin resistance in endocrine disease. | Journal of biomedicine & biotechnology 20100101 |
| Aldosterone-sensitive nucleus tractus solitarius neurons regulate sensitivity of the baroreceptor reflex in high sodium-loaded rats. | Journal of pharmacological sciences 20100101 |
| [Chronic kidney disease and the aldosterone/mineralocorticoid receptor system]. | Nihon Jinzo Gakkai shi 20100101 |
| Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. | Orphanet journal of rare diseases 20100101 |
| Diabetes is an independent predictor of survival 17 years after myocardial infarction: follow-up of the TRACE registry. | Cardiovascular diabetology 20100101 |
| Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective. | BMC dermatology 20100101 |
| [Preoperative and postoperative management of adrenal masses]. | Il Giornale di chirurgia 20100101 |
| Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities. | Cardiology research and practice 20100101 |
| Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats. | Pharmacology 20100101 |
| Adherence to aldosterone-blocking agents in patients with heart failure. | American journal of therapeutics 20100101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| Advances in systolic heart failure. | F1000 medicine reports 20100101 |
| A population approach to eplerenone pharmacokinetics and saturable protein binding. | Drug metabolism and pharmacokinetics 20100101 |
| Successful blood pressure control with additive administration of eplerenone, an aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty. | Internal medicine (Tokyo, Japan) 20100101 |
| Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease. | The open cardiovascular medicine journal 20100101 |
| Signaling of reactive oxygen and nitrogen species in Diabetes mellitus. | Oxidative medicine and cellular longevity 20100101 |
| Evidence-based approach for managing hypertension in type 2 diabetes. | Integrated blood pressure control 20100101 |
| Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness. | Integrated blood pressure control 20100101 |
| Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients? | Integrated blood pressure control 20100101 |
| Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease. | Clinical and experimental nephrology 20091201 |
| At the bottom of the differential diagnosis list: unusual causes of pediatric hypertension. | Pediatric nephrology (Berlin, Germany) 20091101 |
| Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. | European journal of heart failure 20091101 |
| Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. | Journal of the American College of Cardiology 20091027 |
| Heritable forms of hypertension. | Pediatric nephrology (Berlin, Germany) 20091001 |
| Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. | Cardiovascular research 20091001 |
| Blocking aldosterone in heart failure. | Therapeutic advances in cardiovascular disease 20091001 |
| Update in primary aldosteronism. | The Journal of clinical endocrinology and metabolism 20091001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091001 |
| Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. | American journal of physiology. Renal physiology 20090901 |
| Electrophysiological responses of sympathetic preganglionic neurons to ANG II and aldosterone. | American journal of physiology. Regulatory, integrative and comparative physiology 20090901 |
| Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats. | Hypertension (Dallas, Tex. : 1979) 20090901 |
| The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. | American heart journal 20090901 |
| Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. | The Journal of steroid biochemistry and molecular biology 20090801 |
| Aberrant ENaC activation in Dahl salt-sensitive rats. | Journal of hypertension 20090801 |
| The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells. | Hypertension research : official journal of the Japanese Society of Hypertension 20090801 |
| Aldosterone in clinical nephrology--old hormone, new questions. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090801 |
| Effects of aldosterone on Cx43 gap junction expression in neonatal rat cultured cardiomyocytes. | Circulation journal : official journal of the Japanese Circulation Society 20090801 |
| Hypertension of Kcnmb1-/- is linked to deficient K secretion and aldosteronism. | Proceedings of the National Academy of Sciences of the United States of America 20090714 |
| Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20090701 |
| Eplerenone does not attenuate diabetes-associated atherosclerosis. | Journal of hypertension 20090701 |
| Establishment of HPLC-ESI-MS method for the determination of eplerenone in human plasma and its pharmacokinetics. | Yao xue xue bao = Acta pharmaceutica Sinica 20090701 |
| Plasma apelin concentration is depressed following acute myocardial infarction in man. | European journal of heart failure 20090601 |
| New therapeutic options in patients prone to hypertension: a focus on direct Renin inhibition and aldosterone blockade. | The American journal of the medical sciences 20090601 |
| Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. | American journal of physiology. Heart and circulatory physiology 20090601 |
| Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. | Heart rhythm 20090601 |
| Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). | The American journal of cardiology 20090601 |
| Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? | American heart journal 20090601 |
| [The use of aldosterone antagonists in the cardiovascular diseases]. | Kardiologia polska 20090601 |
| [Eplerenone in resistant hypertension with previous spironolactone intolerance]. | Medicina clinica 20090523 |
| A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction. | The American journal of cardiology 20090515 |
| Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. | Circulation 20090512 |
| Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. | Hypertension research : official journal of the Japanese Society of Hypertension 20090501 |
| Prevention of myocardial dysfunction by Eplerenon in experimental tachycardiomyopathy. | Medical science monitor : international medical journal of experimental and clinical research 20090501 |
| Aldosterone Receptor Antagonism Reduces Urinary C-Reactive Protein Excretion in Angiotensin II-Infused, Hypertensive Rats. | Journal of the American Society of Hypertension : JASH 20090501 |
| [Aldosterone antagonists for all patients with heart failure?]. | MMW Fortschritte der Medizin 20090409 |
| Enhancement of aldosterone-induced catecholamine production by bone morphogenetic protein-4 through activating Rho and SAPK/JNK pathway in adrenomedullar cells. | American journal of physiology. Endocrinology and metabolism 20090401 |
| Anti-inflammatory effects of eplerenone on viral myocarditis. | European journal of heart failure 20090401 |
| A comparison of the aldosterone-blocking agents eplerenone and spironolactone. | Clinical cardiology 20090401 |
| The clinical pharmacology of eplerenone. | Expert opinion on drug metabolism & toxicology 20090401 |
| Aldosterone-receptor antagonism in hypertension. | Journal of hypertension 20090401 |
| Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats. | Journal of hypertension 20090401 |
| Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction. | Clinical and translational science 20090401 |
| Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology. | Molecular and cellular endocrinology 20090325 |
| CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. | British journal of cancer 20090310 |
| Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine. | European journal of clinical pharmacology 20090301 |
| Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats. | American journal of physiology. Regulatory, integrative and comparative physiology 20090301 |
| Role of aldosterone receptor antagonist eplerenone in aortic stenosis. | American heart journal 20090301 |
| Eplerenone treatment of aortic stenosis. [letter]. | American heart journal 20090301 |
| Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. | European heart journal 20090201 |
| Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). | Circulation 20090127 |
| Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090101 |
| Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090101 |
| Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? | Nature clinical practice. Oncology 20090101 |
| Eplerenone decreases inflammatory foci in spontaneously hypertensive rat hearts with minimal effects on blood pressure. | Journal of cardiovascular pharmacology 20090101 |
| Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. | BMC endocrine disorders 20090101 |
| Candesartan cilexetil in the treatment of chronic heart failure. | Vascular health and risk management 20090101 |
| A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. | Therapeutics and clinical risk management 20090101 |
| Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. | American journal of nephrology 20090101 |
| Prevention of atherosclerosis by interference with the vascular nitric oxide system. | Current pharmaceutical design 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101 |
| Management of hypertension in the elderly patient. | Clinical interventions in aging 20090101 |
| Review of the treatment of acute coronary syndrome in elderly patients. | Clinical interventions in aging 20090101 |
| Acute diastolic mitral regurgitation as a mechanism of left ventricular failure in a patient with normal systolic function. | Indian heart journal 20090101 |
| Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney. | International journal of nephrology and renovascular disease 20090101 |
| Clinical approach in treatment of resistant hypertension. | Integrated blood pressure control 20090101 |
| Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. | Experimental cell research 20081210 |
| Endocrine arterial hypertension: therapeutic approach in clinical practice. | Minerva endocrinologica 20081201 |
| Eplerenone in patients with acute myocardial infarction complicated by heart failure. | Hypertension (Dallas, Tex. : 1979) 20081201 |
| Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. | Journal of pharmacological sciences 20081201 |
| Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat. | Journal of Korean medical science 20081201 |
| Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. | Regulatory peptides 20081129 |
| Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). | Circulation 20081014 |
| Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit. | Circulation 20081014 |
| [Pharmacology profile and clinical findings of Selara Tablets (eplerenone)]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20081001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20081001 |
| Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080901 |
| Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. | The Journal of clinical endocrinology and metabolism 20080901 |
| Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. | American journal of physiology. Heart and circulatory physiology 20080901 |
| Mineralocorticoid receptor antagonists and endothelial function. | Current opinion in investigational drugs (London, England : 2000) 20080901 |
| Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. | Hypertension research : official journal of the Japanese Society of Hypertension 20080901 |
| Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. | Endocrine regulations 20080901 |
| Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. | Archives of cardiovascular diseases 20080901 |
| Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium. | Biochemical and biophysical research communications 20080822 |
| Aldosterone and glomerular podocyte injury. | Clinical and experimental nephrology 20080801 |
| Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. | Arteriosclerosis, thrombosis, and vascular biology 20080801 |
| History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. | Hypertension (Dallas, Tex. : 1979) 20080801 |
| Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. | Hypertension (Dallas, Tex. : 1979) 20080801 |
| Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. | Circulation journal : official journal of the Japanese Circulation Society 20080801 |
| A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. | American heart journal 20080801 |
| Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. | Cardiovascular research 20080701 |
| Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. | American journal of physiology. Renal physiology 20080701 |
| Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1. | The Journal of steroid biochemistry and molecular biology 20080701 |
| Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. | Journal of hypertension 20080701 |
| Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. | Diabetes, obesity & metabolism 20080601 |
| The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A. | Hypertension research : official journal of the Japanese Society of Hypertension 20080601 |
| [Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart]. | MMW Fortschritte der Medizin 20080529 |
| Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of L-type calcium currents in cultured neonatal cardiomyocytes. | Pflugers Archiv : European journal of physiology 20080501 |
| Therapeutic strategies to slow chronic kidney disease progression. | Pediatric nephrology (Berlin, Germany) 20080501 |
| Eplerenone in the treatment of Gitelman's syndrome. | Internal medicine journal 20080501 |
| Aldosterone-to-renin ratio as a screening test for primary aldosteronism--the Dutch ARRAT Study. | The Netherlands journal of medicine 20080501 |
| Eplerenone ethanol solvate. | Acta crystallographica. Section E, Structure reports online 20080501 |
| Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. | Circulation 20080429 |
| A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. | Endocrine reviews 20080401 |
| Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. | Hypertension (Dallas, Tex. : 1979) 20080401 |
| Translational research goes both ways: lessons from clinical studies. | Clinical and experimental pharmacology & physiology 20080401 |
| Aldosterone and the vascular system. | The Journal of steroid biochemistry and molecular biology 20080401 |
| A comparison of the aldosterone-blocking agents eplerenone and spironolactone. | Clinical cardiology 20080401 |
| Hypertension in children with chronic kidney disease: pathophysiology and management. | Pediatric nephrology (Berlin, Germany) 20080301 |
| Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. | Endocrinology 20080301 |
| Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. | American journal of physiology. Renal physiology 20080301 |
| Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. | Hypertension (Dallas, Tex. : 1979) 20080301 |
| A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. | Hypertension (Dallas, Tex. : 1979) 20080301 |
| Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. | Expert opinion on pharmacotherapy 20080301 |
| Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone. | The European journal of health economics : HEPAC : health economics in prevention and care 20080201 |
| Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. | Hypertension (Dallas, Tex. : 1979) 20080201 |
| Aldosterone receptor blockade in patients with left ventricular systolic dysfunction following acute myocardial infarction. | Cardiology clinics 20080201 |
| Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. | Hypertension research : official journal of the Japanese Society of Hypertension 20080201 |
| [Antialdosteronic agents: their role in heart failure]. | Medicina clinica 20080119 |
| Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. | Nature clinical practice. Endocrinology & metabolism 20080101 |
| Eplerenone after myocardial infarction? | Drug and therapeutics bulletin 20080101 |
| Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats. | Journal of pharmacological and toxicological methods 20080101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080101 |
| Practical aspects in the management of hypokalemic periodic paralysis. | Journal of translational medicine 20080101 |
| Drug therapy for chronic heart failure due to left ventricular systolic dysfunction. II. Diuretics. | Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20080101 |
| [Cardiorenal syndrome]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101 |
| Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need? | Acta medica Indonesiana 20080101 |
| Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. | Journal of the American Society of Hypertension : JASH 20080101 |
| (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor. | Journal of medicinal chemistry 20071227 |
| Eplerenone relieves spironolactone-induced painful gynaecomastia in patients with decompensated hepatitis B-related cirrhosis. | Scandinavian journal of gastroenterology 20071201 |
| Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure. | Cardiovascular drugs and therapy 20071201 |
| Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. | Expert opinion on pharmacotherapy 20071201 |
| Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. | The American journal of medicine 20071201 |
| Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. | Current drug metabolism 20071201 |
| Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. | Current heart failure reports 20071201 |
| [Pathophysiology of heart failure and the biomarkers; brain natriuretic hormone as the class-1 recommendation by the new Japanese Guideline for Heart Failure]. | Rinsho byori. The Japanese journal of clinical pathology 20071201 |
| Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071101 |
| Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. | Hypertension (Dallas, Tex. : 1979) 20071101 |
| Avoiding vicious circles: mineralocorticoid receptor antagonism prevents vascular oxidative stress early after myocardial infarction. | Hypertension (Dallas, Tex. : 1979) 20071101 |
| Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. | Hypertension (Dallas, Tex. : 1979) 20071101 |
| Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration? | Endocrinology 20071001 |
| Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. | Hypertension (Dallas, Tex. : 1979) 20071001 |
| Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. | American journal of physiology. Regulatory, integrative and comparative physiology 20071001 |
| Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. | American journal of hypertension 20071001 |
| Aldosterone antagonism in heart failure. | Vascular health and risk management 20071001 |
| Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. | American journal of physiology. Renal physiology 20070901 |
| [Role of aldosterone in oxidative stress and renal injury]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20070901 |
| [Molecular mechanism of cardiovascular damage induced by aldosterone]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20070901 |
| Acute aldosterone infusion enhances thrombosis development in normotensive rats. | Thrombosis and haemostasis 20070901 |
| Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. | Journal of computer-aided molecular design 20070801 |
| Arterial stiffness and pharmacological interventions--the TRanscend arterial stiffNess Substudy (TRANS study). | Vascular health and risk management 20070801 |
| Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. | European journal of pharmacology 20070702 |
| Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension. | American journal of physiology. Renal physiology 20070701 |
| Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. | The Journal of clinical endocrinology and metabolism 20070701 |
| Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues. | Nature clinical practice. Cardiovascular medicine 20070701 |
| [Aldosterone receptor antagonists]. | Revue medicale suisse 20070530 |
| [Eplerenone for treatment of heart failure]. | Nihon rinsho. Japanese journal of clinical medicine 20070528 |
| [Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects]. | Nihon rinsho. Japanese journal of clinical medicine 20070528 |
| Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. | American journal of physiology. Renal physiology 20070501 |
| Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070501 |
| Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. | Journal of cardiovascular pharmacology 20070501 |
| [Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study]. | Nihon rinsho. Japanese journal of clinical medicine 20070428 |
| Primary percutaneous coronary intervention. | The New England journal of medicine 20070412 |
| Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. | Endocrinology 20070401 |
| A German family with glucocorticoid-remediable aldosteronism. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070401 |
| Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? | Clinical research in cardiology : official journal of the German Cardiac Society 20070401 |
| Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? | Expert opinion on pharmacotherapy 20070401 |
| Current guidelines for treatment of heart failure: 2006 update. | Pharmacotherapy 20070401 |
| Increased cyclooxygenase-2 expression in hypothalamic paraventricular nucleus in rats with heart failure: role of nuclear factor kappaB. | Hypertension (Dallas, Tex. : 1979) 20070301 |
| Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. | Journal of hypertension 20070301 |
| Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. | Journal of hypertension 20070301 |
| Mineralocorticoid receptor antagonists. | Current hypertension reports 20070301 |
| Rapid effects of aldosterone on clonal human vascular smooth muscle cells. | American journal of physiology. Cell physiology 20070201 |
| Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. | American journal of physiology. Regulatory, integrative and comparative physiology 20070201 |
| Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. | Hypertension (Dallas, Tex. : 1979) 20070201 |
| Eplerenone suppresses neointima after coronary stenting in pigs: could it be extrapolated to stent restenosis in humans? | International journal of cardiology 20070131 |
| Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats. | International journal of cardiology 20070102 |
| Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. | American journal of physiology. Heart and circulatory physiology 20070101 |
| Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070101 |
| Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. | Journal of hypertension 20070101 |
| Aldosterone antagonists: the most underutilized class of heart failure medications. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101 |
| Update of diuretics in the treatment of hypertension. | American journal of therapeutics 20070101 |
| Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. | European journal of heart failure 20070101 |
| The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. | Nuclear receptor signaling 20070101 |
| [Pathophysiological role of aldosterone in acute renal failure]. | Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 20070101 |
| The risks and benefits of therapy with aldosterone receptor antagonist therapy. | Current drug safety 20070101 |
| Heart failure. | BMJ clinical evidence 20070101 |
| The role of the glucocorticoid receptor in mineralocorticoid/salt-mediated cardiac fibrosis. | Endocrinology 20061201 |
| Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor. | Apoptosis : an international journal on programmed cell death 20061201 |
| Why are mineralocorticoid receptor antagonists cardioprotective? | Naunyn-Schmiedeberg's archives of pharmacology 20061201 |
| Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. | Journal of the American Society of Nephrology : JASN 20061201 |
| Sexual function in hypertensive patients receiving treatment. | Vascular health and risk management 20061201 |
| Candesartan in heart failure. | Clinical interventions in aging 20061201 |
| Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. | Endocrinology 20061101 |
| Does eplerenone have a future in the management of hypertension in Europe? | Journal of human hypertension 20061101 |
| Antiangiogenic effects of spironolactone and other potassium-sparing diuretics in human umbilical vein endothelial cells and in fibrin gel chambers implanted in rats. | Journal of hypertension 20061101 |
| Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. | The American journal of medicine 20061101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061101 |
| [Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure]. | Deutsche medizinische Wochenschrift (1946) 20061013 |
| Aldosterone blockade in post-acute myocardial infarction heart failure. | Clinical cardiology 20061001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061001 |
| Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. | Circulation research 20060929 |
| [Antihypertensive agents used as first line agents: beta-blockers under pressure]. | Revue medicale suisse 20060913 |
| [The revived interest in aldosterone antagonists]. | Revue medicale suisse 20060913 |
| [Modern pharmacological aspects of hyperaldosteronism therapy]. | Der Internist 20060901 |
| Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice. | Clinical and experimental pharmacology & physiology 20060901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060901 |
| Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. | Clinical journal of the American Society of Nephrology : CJASN 20060901 |
| Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. | Future cardiology 20060901 |
| MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. | The American journal of pathology 20060801 |
| Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. | Hypertension research : official journal of the Japanese Society of Hypertension 20060801 |
| Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in deoxycorticosterone/salt rats. | Endocrinology 20060701 |
| Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. | Hypertension (Dallas, Tex. : 1979) 20060701 |
| Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure. | Heart (British Cardiac Society) 20060701 |
| [Cardiovascular action of aldosterone]. | Nihon rinsho. Japanese journal of clinical medicine 20060701 |
| [Cardioprotective effect of aldosterone antagonists for ventricular remodeling]. | Nihon rinsho. Japanese journal of clinical medicine 20060701 |
| [Aldosterone receptor blockade after acute myocardial infarction with heart failure]. | Medizinische Klinik (Munich, Germany : 1983) 20060615 |
| [Combination drug therapy after myocardial infarction. Early aldosterone blocking protects risk patients]. | MMW Fortschritte der Medizin 20060615 |
| Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. | Hypertension (Dallas, Tex. : 1979) 20060601 |
| Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition? | Journal of hypertension 20060601 |
| Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. | Cardiovascular drugs and therapy 20060601 |
| Valsartan in the treatment of heart attack survivors. | Vascular health and risk management 20060601 |
| [Deficiency of 11beta-hydroxysteroid dehydrogenase type 2 (syndrome of apparent mineralocorticoid excess)]. | Nihon rinsho. Japanese journal of clinical medicine 20060528 |
| Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. | The American journal of cardiology 20060522 |
| Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. | The American journal of cardiology 20060522 |
| A new approach to the furan degradation problem involving ozonolysis of the trans-enedione and its use in a cost-effective synthesis of eplerenone. | Organic letters 20060511 |
| Protective effect of spironolactone on endothelial cell apoptosis. | Endocrinology 20060501 |
| Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. | European journal of heart failure 20060501 |
| Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. | Journal of cardiovascular electrophysiology 20060501 |
| Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure. | Journal of cardiovascular electrophysiology 20060501 |
| [Antihypertensive drugs in clinical development]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20060501 |
| Hypertension and ethnic group: eplerenone may have role in hypertension related atrial fibrillation. | BMJ (Clinical research ed.) 20060422 |
| Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. | Arteriosclerosis, thrombosis, and vascular biology 20060401 |
| Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? | Hypertension (Dallas, Tex. : 1979) 20060401 |
| Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. | Hypertension (Dallas, Tex. : 1979) 20060401 |
| Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. | Hypertension (Dallas, Tex. : 1979) 20060401 |
| Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. | Hypertension (Dallas, Tex. : 1979) 20060401 |
| The pharmacological treatment of primary aldosteronism. | Expert opinion on pharmacotherapy 20060401 |
| Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too. | Prescrire international 20060401 |
| Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard? | Cardiovascular & hematological agents in medicinal chemistry 20060401 |
| The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. | Cardiovascular drugs and therapy 20060401 |
| Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. | Hypertension research : official journal of the Japanese Society of Hypertension 20060401 |
| Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. | Endocrinology 20060301 |
| Aldosterone receptor antagonists for heart failure: current status, future indications. | Cleveland Clinic journal of medicine 20060301 |
| Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20060301 |
| Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20060301 |
| Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20060301 |
| Eplerenone suppresses neointimal formation after coronary stent implantation in swine. | International journal of cardiology 20060215 |
| Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats. | Clinical and experimental hypertension (New York, N.Y. : 1993) 20060201 |
| Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction. | Evidence-based medicine 20060201 |
| [The latest developments in endocrinology 2004/2005]. | Medizinische Klinik (Munich, Germany : 1983) 20060115 |
| Aldosterone antagonists in the treatment of heart failure. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060101 |
| Adjunctive treatment with eplerenone reduced 30-day all-cause mortality in acute myocardial infarction. | ACP journal club 20060101 |
| Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. | Journal of pharmacological sciences 20060101 |
| Hospital protocols and evidence-based therapies: the importance of integrating aldosterone blockade into the management of patients with post-acute myocardial infarction heart failure. | Clinical cardiology 20060101 |
| Mineralocorticoid receptor blockade in the protection of target organ damage. | Cardiovascular & hematological agents in medicinal chemistry 20060101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060101 |
| [Diuretic therapy in heart failure]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20060101 |
| [Contemporary approaches to the treatment of chronic heart failure in adults (after materials of recommendations of American College of Cardiology and American Heart Association, 2005)]. | Kardiologiia 20060101 |
| Aldosterone remodels human endothelium. | Acta physiologica (Oxford, England) 20060101 |
| Application of continuous positive airway pressure in hypoxemic acute respiratory failure associated with diastolic dysfunction in pregnancy. | Congestive heart failure (Greenwich, Conn.) 20060101 |
| Cardiomyopathy, familial dilated. | Orphanet journal of rare diseases 20060101 |
| Aldosterone and thrombosis formation: implications for ischemic and atherosclerotic heart disease. | Journal of endocrinological investigation 20060101 |
| Pfizer launches Inspra for heart failure. | Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20060101 |
| Eplerenone reduces morbidity and mortality after acute MI. | Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20060101 |
| Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure. | Cardiovascular revascularization medicine : including molecular interventions 20060101 |
| Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. | Heart (British Cardiac Society) 20051201 |
| Mechanisms for nongenomic and genomic effects of aldosterone on Na+/H+ exchange in vascular smooth muscle cells. | Journal of hypertension 20051201 |
| Aldosterone antagonists in the treatment and prevention of heart failure. | Current treatment options in cardiovascular medicine 20051201 |
| Does eplerenone benefit postinfarction patients with heart failure and left ventricular systolic dysfunction? | Nature clinical practice. Cardiovascular medicine 20051201 |
| Aldosterone receptor antagonists in the medical management of chronic heart failure. | Mayo Clinic proceedings 20051201 |
| [Heart failure after myocardial infarction. Increased risk, poorer treatment]. | MMW Fortschritte der Medizin 20051201 |
| [Efficient improvement of prognosis after myocardial infarct? Additional aldosterone inhibition is required]. | MMW Fortschritte der Medizin 20051201 |
| The genetic basis for altered blood vessel function in disease: large artery stiffening. | Vascular health and risk management 20051201 |
| Eplerenone inhibits atherosclerosis in nonhuman primates. | Hypertension (Dallas, Tex. : 1979) 20051101 |
| Eplerenone antagonizes atherosclerosis, but what is the agonist? | Hypertension (Dallas, Tex. : 1979) 20051101 |
| Mineralocorticoid-receptor blockade, hypertension and heart failure. | Nature clinical practice. Endocrinology & metabolism 20051101 |
| Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. | Circulation research 20051028 |
| Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. | Hypertension (Dallas, Tex. : 1979) 20051001 |
| Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. | Hypertension (Dallas, Tex. : 1979) 20051001 |
| Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. | Hypertension (Dallas, Tex. : 1979) 20051001 |
| c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. | Hypertension (Dallas, Tex. : 1979) 20051001 |
| Sudden death in patients with myocardial infarction. | The New England journal of medicine 20050922 |
| Effects of eplerenone versus losartan in patients with low-renin hypertension. | American heart journal 20050901 |
| Beneficial cardiovascular actions of eplerenone in the spontaneously hypertensive rat. | Journal of cardiovascular pharmacology and therapeutics 20050901 |
| Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction? | Nature clinical practice. Cardiovascular medicine 20050901 |
| Eplerenone appears cost-effective for people with heart failure after acute myocardial infarction. Commentary 1. | Evidence-based cardiovascular medicine 20050901 |
| Eplerenone appears cost-effective for people with heart failure after acute myocardial infarction. Commentary 2. | Evidence-based cardiovascular medicine 20050901 |
| Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. | Journal of the American College of Cardiology 20050802 |
| Letter regarding article by Weintraub et al, 'Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure'. | Circulation 20050802 |
| The risks and benefits of aldosterone antagonists. | Current heart failure reports 20050801 |
| Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. | Mini reviews in medicinal chemistry 20050801 |
| Heart failure after acute ST-segment elevation myocardial infarction: what should we do about it? | Clinical cardiology 20050801 |
| New aldosteron receptor inhibitors in heart failure. | Minerva cardioangiologica 20050801 |
| Aldosterone receptor antagonism in heart failure. | Pharmacotherapy 20050801 |
| [Roll of aldosterone in pathogenesis of kidney disorders]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050710 |
| [Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate]. | MMW Fortschritte der Medizin 20050707 |
| [Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis]. | MMW Fortschritte der Medizin 20050707 |
| Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. | Cardiovascular research 20050701 |
| Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. | Journal of clinical pharmacology 20050701 |
| Role of cardiovascular aldosterone in hypertension. | Current medicinal chemistry. Cardiovascular and hematological agents 20050701 |
| [Explanation on indications and cost-efficiency of Inspra]. | Lakartidningen 20050701 |
| [Inspra and the drug benefits board: What is the role of the drug committees?]. | Lakartidningen 20050701 |
| The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. | Molecular endocrinology (Baltimore, Md.) 20050601 |
| Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. | Journal of hypertension 20050601 |
| Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. | Current hypertension reports 20050601 |
| Aldosterone receptor antagonists: biology and novel therapeutic applications. | Current hypertension reports 20050601 |
| [An addition concerning spironolactone and eplerenone (Inspra) in heart failure]. | Lakartidningen 20050601 |
| [Recent insights into the role of aldosterone in physiology, pathology and therapy]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20050601 |
| The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. | Molecular pharmacology 20050501 |
| Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. | Heart (British Cardiac Society) 20050501 |
| [The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design]. | Italian heart journal : official journal of the Italian Federation of Cardiology 20050501 |
| [LFN's evaluation of Inspra illustrates the need of drug committees!]. | Lakartidningen 20050501 |
| [The role of aldosterone-antagonists in the treatment of congestive heart failure]. | Orvosi hetilap 20050403 |
| Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. | Hypertension (Dallas, Tex. : 1979) 20050401 |
| Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. | Hypertension (Dallas, Tex. : 1979) 20050401 |
| Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. | Hypertension (Dallas, Tex. : 1979) 20050401 |
| Aldosterone as a cardiovascular risk factor. | Trends in endocrinology and metabolism: TEM 20050401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050401 |
| Implantable cardioverter-defibrillator therapy after myocardial infarction. | The New England journal of medicine 20050310 |
| Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. | Circulation 20050308 |
| Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. | Endocrinology 20050301 |
| [Aldosterone and aldosterone antagonists. Eplerenone in cardiac insufficiency after myocardial infarction]. | Medizinische Monatsschrift fur Pharmazeuten 20050301 |
| [Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)]. | Nihon rinsho. Japanese journal of clinical medicine 20050301 |
| [Aldosterone antagonist therapy for chronic heart failure]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050210 |
| Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. | Pharmacology 20050201 |
| Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. | Circulation 20050201 |
| [Aldosterone and magnesium]. | Clinical calcium 20050201 |
| 2004 drug approval highlights: FDA update. | The Nurse practitioner 20050201 |
| RALES, EPHESUS and redox. | The Journal of steroid biochemistry and molecular biology 20050201 |
| Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. | The Annals of pharmacotherapy 20050101 |
| Eplerenone: a review of its use in essential hypertension. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101 |
| A new selective aldosterone antagonist. Inspra's role in hypertension and post-MI heart failure. | Advance for nurse practitioners 20050101 |
| Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction. | Clinical cardiology 20050101 |
| Interactions of high salt intake and the response of the cardiovascular system to aldosterone. | Cardiology in review 20050101 |
| Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. | Heart failure reviews 20050101 |
| Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. | Heart failure reviews 20050101 |
| The role of aldosterone blockade in patients with heart failure. | Heart failure reviews 20050101 |
| Antihypertensive therapy: role of aldosterone antagonists. | Current pharmaceutical design 20050101 |
| Vitamin A deficiency alters the pulmonary parenchymal elastic modulus and elastic fiber concentration in rats. | Respiratory research 20050101 |
| Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. | Antioxidants & redox signaling 20050101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050101 |
| [The place of aldosterone receptor blockers in the treatment of chronic heart failure]. | Kardiologiia 20050101 |
| Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure. | PharmacoEconomics 20050101 |
| Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure. | Fiziologiia cheloveka 20050101 |
| Aldosterone in heart and kidney diseases. | Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20050101 |
| [Novel action of aldosterone in CsA nephrotoxicity]. | Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 20050101 |
| Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction. | Core evidence 20050101 |
| Eplerenone in hypertension. | Expert opinion on pharmacotherapy 20041201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20041201 |
| The use of aldosterone receptor blockers in the treatment of hypertension. | Journal of clinical hypertension (Greenwich, Conn.) 20041101 |
| New pharmacological strategies in chronic heart failure. | Cardiovascular drugs and therapy 20041101 |
| Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. | Hypertension research : official journal of the Japanese Society of Hypertension 20041101 |
| [Therapy of heart failure after myocardial infarction. With eplerenone a new course]. | MMW Fortschritte der Medizin 20041021 |
| [More benefit in hypertension and high-grade reduction of the pump performance. Earlier beginning of therapy maximizes the benefit]. | MMW Fortschritte der Medizin 20041021 |
| Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. | Current medicinal chemistry. Cardiovascular and hematological agents 20041001 |
| The use of selective aldosterone antagonists. | Current hypertension reports 20041001 |
| Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. | Journal of cardiac failure 20041001 |
| Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. | Clinical and experimental pharmacology & physiology 20041001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20041001 |
| Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. | Diabetes & metabolism 20040901 |
| Aldosterone blockade in heart failure. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20040901 |
| Reassessing guidelines for heart failure. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20040901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040901 |
| Prognostic value of health status in patients with heart failure after acute myocardial infarction. | Circulation 20040803 |
| Mineralocorticoid receptor antagonists and hypertension: is there a rationale? | Current hypertension reports 20040801 |
| Aldosterone-receptor antagonism and end-stage renal disease. | Current hypertension reports 20040801 |
| [Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20040801 |
| The clinical implications of aldosterone escape in congestive heart failure. | European journal of heart failure 20040801 |
| [Aldosterone]. | Rinsho byori. The Japanese journal of clinical pathology 20040801 |
| Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. | Endocrinology 20040701 |
| Eplerenone: will it have a role in the treatment of acute coronary syndromes? | Current cardiology reports 20040701 |
| Aldosterone in the development and progression of renal injury. | Kidney international 20040701 |
| Aldosterone antagonism and congestive heart failure: a new look at an old therapy. | Current opinion in cardiology 20040701 |
| Inspra improves survival for CHF patients. | The Nurse practitioner 20040701 |
| Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. | Hypertension (Dallas, Tex. : 1979) 20040601 |
| Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. | Hypertension (Dallas, Tex. : 1979) 20040601 |
| Aldosterone and aldosterone antagonism in systemic hypertension. | Current hypertension reports 20040601 |
| Distinguishing the antihypertensive and electrolyte effects of eplerenone. | The Journal of clinical endocrinology and metabolism 20040601 |
| Eplerenone: a new selective aldosterone receptor antagonist. | Drugs of today (Barcelona, Spain : 1998) 20040601 |
| Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. | Circulation 20040511 |
| [Primary prevention of sudden cardiac death]. | Deutsche medizinische Wochenschrift (1946) 20040507 |
| Eplerenone in the treatment of chronic heart failure. | Expert review of cardiovascular therapy 20040501 |
| Role of aldosterone blockade in managing heart failure: new and emerging treatment options. Introduction. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040501 |
| Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040501 |
| Integrating traditional and emerging treatment options in heart failure. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040501 |
| Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. | Hypertension research : official journal of the Japanese Society of Hypertension 20040501 |
| Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. | The American journal of cardiology 20040415 |
| Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. | Hypertension (Dallas, Tex. : 1979) 20040401 |
| Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. | Journal of clinical hypertension (Greenwich, Conn.) 20040401 |
| Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. | American heart journal 20040401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040401 |
| Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. | Proceedings (Baylor University. Medical Center) 20040401 |
| The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. | Molecular and cellular endocrinology 20040331 |
| The evolution of aldosterone antagonists. | Molecular and cellular endocrinology 20040331 |
| The 45-year story of the development of an anti-aldosterone more specific than spironolactone. | Molecular and cellular endocrinology 20040331 |
| Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. | Molecular and cellular endocrinology 20040331 |
| Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. | Molecular and cellular endocrinology 20040331 |
| Aldosterone target organ protection by eplerenone. | Molecular and cellular endocrinology 20040331 |
| Review of aldosterone- and angiotensin II-induced target organ damage and prevention. | Cardiovascular research 20040301 |
| [Significance of aldosterone antagonist therapy]. | Der Internist 20040301 |
| The resurrection of spironolactone on its golden anniversary. | American journal of critical care : an official publication, American Association of Critical-Care Nurses 20040301 |
| New therapies for heart failure. | RN 20040301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040301 |
| Role of the selective aldosterone receptor blockers in arterial hypertension. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20040301 |
| Ask the doctors. I read about a new drug for heart failure called eplerenone. How does it work? Is it safe? | Heart advisor 20040301 |
| The association between congestive heart failure and chronic renal disease. | Current opinion in nephrology and hypertension 20040301 |
| Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. | Xenobiotica; the fate of foreign compounds in biological systems 20040301 |
| Trial suggests that combining eplerenone and enalapril reduces left ventricular hypertrophy in hypertension more effectively than either treatment alone. | Evidence-based cardiovascular medicine 20040301 |
| Eplerenone (Inspra) for hypertension. | American family physician 20040215 |
| Aldosterone antagonism and arterial stiffness. | Hypertension (Dallas, Tex. : 1979) 20040201 |
| Role of a selective aldosterone blocker in mice with chronic heart failure. | Journal of cardiac failure 20040201 |
| Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. | Hypertension (Dallas, Tex. : 1979) 20040101 |
| Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. | American journal of nephrology 20040101 |
| Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. | American journal of nephrology 20040101 |
| The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. | Expert review of cardiovascular therapy 20040101 |
| New drugs of 2003. | Journal of the American Pharmacists Association : JAPhA 20040101 |
| The role of aldosterone and aldosterone-receptor antagonists in heart failure. | Reviews in cardiovascular medicine 20040101 |
| Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease. | Journal of the American Pharmacists Association : JAPhA 20040101 |
| New treatment option for heart failure patients: eplerenone. | The Journal of cardiovascular nursing 20040101 |
| Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. | Drugs 20040101 |
| The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. | Expert opinion on investigational drugs 20031201 |
| [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. | MMW Fortschritte der Medizin 20031120 |
| Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. | Journal of the American College of Cardiology 20031105 |
| Aldosterone antagonism and myocardial infarction: from animals to man and back. | Journal of the American College of Cardiology 20031105 |
| Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? | Journal of clinical pharmacology 20031101 |
| Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. | Drug metabolism and disposition: the biological fate of chemicals 20031101 |
| The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. | Clinical therapeutics 20031101 |
| Avoid the risks of mixed medications. How to minimize dangerous interactions with cardiovascular drugs. | Heart advisor 20031101 |
| [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction]. | MMW Fortschritte der Medizin 20031030 |
| Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. | Circulation 20031014 |
| Aldosterone blockade in patients with systolic left ventricular dysfunction. | Circulation 20031014 |
| Two better than one. | Circulation 20031014 |
| RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. | Current hypertension reports 20031001 |
| Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20031001 |
| Ask the doctor. I am a 50-year-old man with congestive heart failure. My doctor has me on all the usual drugs, and a couple of years ago added spironolactone. I did okay with it for a while, but then began to notice that my breasts were getting bigger and began to hurt. My doctor agreed that I should stop taking spironolactone, but I wonder if I am missing out on something. | Harvard heart letter : from Harvard Medical School 20031001 |
| Inspra. | Discovery medicine 20031001 |
| Aldosterone blockade after myocardial infarction. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030902 |
| Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction? | Expert opinion on pharmacotherapy 20030901 |
| New developments in the management of hypertension. | American family physician 20030901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030901 |
| Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. | Clinical therapeutics 20030901 |
| Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20030901 |
| Aldosterone blockade and vascular calcification in hemodialysis patients. | The American journal of medicine 20030815 |
| Selective aldosterone blockade with eplerenone in patients with congestive heart failure. | Expert opinion on investigational drugs 20030801 |
| Primary aldosteronism - treatment options. | Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 20030801 |
| Aldosterone receptor antagonists in the treatment of heart failure. | Connecticut medicine 20030801 |
| Aldosterone receptor antagonists: biology and novel therapeutical applications. | Journal of endocrinological investigation 20030801 |
| Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. | Archives of internal medicine 20030714 |
| Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. | Circulation research 20030711 |
| Eplerenone in patients with left ventricular dysfunction. | The New England journal of medicine 20030703 |
| Eplerenone in patients with left ventricular dysfunction. | The New England journal of medicine 20030703 |
| Eplerenone in patients with left ventricular dysfunction. | The New England journal of medicine 20030703 |
| Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. | The American journal of cardiology 20030701 |
| Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. | Journal of cardiovascular pharmacology 20030601 |
| Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. | Thrombosis and haemostasis 20030601 |
| Aldosterone resurgens--letter from EPHESUS. | The Journal of clinical endocrinology and metabolism 20030601 |
| Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. | Cardiovascular research 20030601 |
| Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans. | European journal of heart failure 20030601 |
| Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION. | Journal of cardiac failure 20030601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030601 |
| Aldosterone blockade in patients with acute myocardial infarction. | Circulation 20030527 |
| Eplerenone: cardiovascular protection. | Circulation 20030520 |
| Eplerenone (Inspra). | The Medical letter on drugs and therapeutics 20030512 |
| Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. | Kidney international 20030501 |
| Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. | Hypertension (Dallas, Tex. : 1979) 20030501 |
| New developments in the pharmacological treatment of chronic heart failure. | Expert opinion on investigational drugs 20030501 |
| More hope for heart failure. Findings suggest expanded use of aldosterone-blockers. | Health news (Waltham, Mass.) 20030501 |
| Aldosterone antagonism and hypertension. | Clinical cardiology 20030501 |
| Development and validation of a liquid chromatography-tandem mass spectrometric assay for Eplerenone and its hydrolyzed metabolite in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030425 |
| [Which patient needs an aldosterone antagonist?]. | MMW Fortschritte der Medizin 20030417 |
| Aldosterone blockade and heart failure. | The New England journal of medicine 20030403 |
| Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. | The New England journal of medicine 20030403 |
| Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. | Journal of the American College of Cardiology 20030402 |
| Hypertension, angiotensin II, aldosterone, and race. | Journal of the American College of Cardiology 20030402 |
| Nongenomic effect of aldosterone on Na+,K+-adenosine triphosphatase in arterial vessels. | Endocrinology 20030401 |
| Amiloride reduces stroke and renalinjury in stroke-prone hypertensive rats. | American journal of hypertension 20030401 |
| New antihypertensive drug class. | The American journal of nursing 20030401 |
| Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. | Minerva cardioangiologica 20030401 |
| Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. | Endocrinology 20030301 |
| Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. | Current opinion in nephrology and hypertension 20030301 |
| Eplerenone. | Nature reviews. Drug discovery 20030301 |
| Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. | Xenobiotica; the fate of foreign compounds in biological systems 20030301 |
| Aldosterone as a target in congestive heart failure. | The Medical clinics of North America 20030301 |
| Eplerenone. Pharmacia. | Current opinion in investigational drugs (London, England : 2000) 20030301 |
| A validated SPE-LC-MS/MS assay for Eplerenone and its hydrolyzed metabolite in human urine. | Journal of pharmaceutical and biomedical analysis 20030205 |
| [Aldosterone and its antagonists in heart failure]. | Presse medicale (Paris, France : 1983) 20030118 |
| Aldosterone receptor antagonists: focus on eplerenone. | Progress in cardiovascular nursing 20030101 |
| Eplerenone, a new selective aldosterone blocker. | Current pharmaceutical design 20030101 |
| Aldosterone receptor blockade: a therapy resurrected. | Heart disease (Hagerstown, Md.) 20030101 |
| Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). | Heart disease (Hagerstown, Md.) 20030101 |
| Eplerenone: a selective aldosterone blocker. | Cardiovascular drug reviews 20030101 |
| Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. | Congestive heart failure (Greenwich, Conn.) 20030101 |
| [Anti-angiogenic effects of aldosterone antagonists in the fibrin chamber in rats]. | Archives des maladies du coeur et des vaisseaux 20030101 |
| Adjunctive treatment with eplerenone reduced morbidity and mortality in acute myocardial infarction. | ACP journal club 20030101 |
| Aldosterone receptor antagonists for hypertension: what do they offer? | Drugs 20030101 |
| [Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS]. | Kardiologiia 20030101 |
| Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. | Heart disease (Hagerstown, Md.) 20030101 |
| New therapy update. Inspra (eplerenone tablets). | Congestive heart failure (Greenwich, Conn.) 20030101 |
| The European Society of Cardiology working group on heart failure: Heart Failure Update 2003. | Heart failure monitor 20030101 |
| Trends and treatment of heart failure developing after acute myocardial infarction. | The American heart hospital journal 20030101 |
| Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. | Circulation 20021203 |
| Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. | Drug metabolism and disposition: the biological fate of chemicals 20021201 |
| Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. | Endocrinology 20021201 |
| Do diuretics and aldosterone receptor antagonists improve ventricular remodeling? | Journal of cardiac failure 20021201 |
| Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. | Circulation 20021126 |
| Aldosterone induces a vascular inflammatory phenotype in the rat heart. | American journal of physiology. Heart and circulatory physiology 20021101 |
| New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. | American heart journal 20021101 |
| Clinical implications of aldosterone blockade. | American heart journal 20021101 |
| Eplerenone--a novel selective aldosterone blocker. | The Annals of pharmacotherapy 20021001 |
| The role of aldosterone receptor blockade in the management of cardiovascular disease. | Current opinion in investigational drugs (London, England : 2000) 20021001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021001 |
| [Selective aldosterone blocker for hypertension and heart failure. Better tolerance than previous drugs]. | MMW Fortschritte der Medizin 20020926 |
| The pathophysiology of aldosterone in the cardiovascular system. | Annals of the New York Academy of Sciences 20020901 |
| Gateways to Clinical Trials. | Methods and findings in experimental and clinical pharmacology 20020901 |
| Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. | Hypertension (Dallas, Tex. : 1979) 20020801 |
| Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia. | Hypertension (Dallas, Tex. : 1979) 20020801 |
| Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. | American journal of hypertension 20020801 |
| Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. | Journal of the American College of Cardiology 20020703 |
| Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. | Journal of pharmaceutical sciences 20020601 |
| Mineralocorticoid receptor antagonism in experimental atherosclerosis. | Circulation 20020507 |
| Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). | American heart journal 20020401 |
| Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing. | Journal of pharmaceutical sciences 20020301 |
| Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. | Hypertension (Dallas, Tex. : 1979) 20020201 |
| Aldosterone as a mediator in cardiovascular injury. | Cardiology in review 20020101 |
| Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate? | Journal of clinical hypertension (Greenwich, Conn.) 20020101 |
| Aldosterone 2001. | Trends in endocrinology and metabolism: TEM 20011001 |
| Effect of a selective aldosterone receptor antagonist in myocardial infarction. | American journal of physiology. Heart and circulatory physiology 20010801 |
| Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA). | International journal of cardiology 20010801 |
| Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. | Circulation 20010724 |
| Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20010401 |
| Eplerenone (GD Searle & Co). | Current opinion in investigational drugs (London, England : 2000) 20010401 |
| Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. | Current opinion in pharmacology 20010401 |
| Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. | Hypertension (Dallas, Tex. : 1979) 20010201 |
| New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study. | Cardiovascular drugs and therapy 20010101 |
| The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. | Cardiovascular drugs and therapy 20010101 |
| Eplerenone: a selective aldosterone receptor antagonist (SARA). | Cardiovascular drug reviews 20010101 |